Liang Qiao

3PUBLICATIONS

19CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Jun 18, 2026

HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation-Mediated TXNRD1 Stabilization to Suppress Ferroptosis.

|Sep 10, 2024

Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling.

Yunxing Shi, Zongfeng Wu, Shaoru Liu

|May 08, 2024

Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.

Liang Qiao, Wei He, Guoying Wang

Pageof 1

Frequent Collaborators

3 joint publications

Yunfei Yuan

2 joint publications

Binkui Li

1 joint publications

Guoying Wang

1 joint publications

Guocan Wang

1 joint publications

Binkui Li

1 joint publications

Yi Zeng

1 joint publications

Zhenkun Huang

1 joint publications

Jiliang Qiu

1 joint publications

Guifang Yuan

1 joint publications

Shaoru Liu

Frequent Collaborators

3 joint publications

Yunfei Yuan

2 joint publications

Binkui Li

1 joint publications

Guoying Wang

1 joint publications

Guocan Wang